Adam Feuerstein articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2014/04/09 21:17
2014/04/09 21:17
7d
STEVENSON, Md.--(BUSINESS WIRE)--Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on...
2014/04/09 21:17
2014/04/09 21:17
Latest videos
2014/04/08 14:22
2014/04/08 14:22
8d
Are you still crying over the biotech sector's collapse? Are you arguing about Gilead Sciences'(GILD) valuation with the earnest analyst Mark Schoenebaum or that snarky savant Adam Feuerstein until...
2014/04/06 15:22
2014/04/06 15:22
10d
SAN DIEGO (TheStreet) -- The Agios Pharmaceuticals(AGIO) cancer metabolism drug AG-221 is demonstrating surprisingly strong clinical activity, including multiple complete remissions, in an early stage...
2014/04/04 18:22
2014/04/04 18:22
12d
Biotech Selloff Causes Nasdaq to Drop Over 2% The volatile biotech sector is experiencing extreme selling on Friday, pushing the NASDAQ down over 2%. Sr. Biotech Editor Adam Feuerstein says the...
2014/04/03 13:22
2014/04/03 13:22
13d
Northwest Bio Warns FDA May Throw Out Phase III Brain Cancer Study By: Adam Feuerstein | 04/03/14 - 08:30 AM EDT Northwest Biotherapeutics(NWBO) snuck a brand new risk nugget about the brain cancer...
2014/04/03 13:22
2014/04/03 13:22
13d
Tradable Biotech Stocks Events For the Second Quarter By: Adam Feuerstein | 04/03/14 - 09:00 AM EDT The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a...
2014/04/02 10:22
2014/04/02 10:22
14d
Mannkind(MNKD) won the support of an FDA advisory panel Tuesday for its rapid-acting inhaled insulin Afrezza. By a 13-1 margin, experts on the panel voted to recommend the approval of Afrezza as a new...
2014/03/31 11:22
2014/03/31 11:22
16d
Prana Alzheimer's Study Fails By: Adam Feuerstein | 03/31/14 - 06:54 AM EDT Shares of Prana are down 75% to $2.51 in pre-market trading. The experimental PBT2 did not meet the study's primary...
2014/03/27 21:22
2014/03/27 21:22
20d
Northwest Bio CEO Discloses More Problems With DC-Vax Brain Cancer Study By: Adam Feuerstein | 03/27/14 - 04:21 PM EDT Northwest Biotherapeutics(NWBO) CEO Linda Powers took to a podium at a...
2014/03/26 22:22
2014/03/26 22:22
21d
Novartis Targeted Lung Cancer Drug Highlighted in This Week's NEJM By: Adam Feuerstein | 03/26/14 - 05:14 PM EDT This week's issue of the New England Journal of Medicine includes a study of...
2014/03/26 16:22
2014/03/26 16:22
21d
Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis By: Adam Feuerstein | 03/26/14 - 11:42 AM EDT Disappointment and doubt about Exelixis'(EXEL) prostate cancer drug...
2014/03/26 14:22
2014/03/26 14:22
21d
Insmed's Mixed Lung Infection Data Will be Debated by Bulls and Bears By: Adam Feuerstein | 03/26/14 - 10:03 AM EDT Insmed's(INSM) inhaled antibiotic Arikayce failed to demonstrate a clinical...
2014/03/25 19:22
2014/03/25 19:22
22d
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction' By: Adam Feuerstein | 03/25/14 - 02:35 PM EDT A list that might be interesting only to me, but I will share anyway: The...
2014/03/25 18:22
2014/03/25 18:22
22d
Galectin: Mark The Date. Drug Data Are Coming And We're Selling Stock. By: Adam Feuerstein | 03/25/14 - 01:29 PM EDT Galectin Therapeutics(GALT) issued a press release this morning, informing...
2014/03/24 20:22
2014/03/24 20:22
23d
Don't Hate Josh Brown For Calling Biotech a Bubble. Learn From Him. By: Adam Feuerstein | 03/24/14 - 04:17 PM EDT The best commentary on the biotech meltdown today came from an outsider. Josh Brown,...
2014/03/24 10:22
2014/03/24 10:22
23d
A Monday Biotech Trading Primer Following Friday's Scary Selloff By: Adam Feuerstein | 03/24/14 - 06:12 AM EDT Let's take a look at where things stand. The Nasdaq Biotechnology Index (NBI) ended...
2014/03/21 16:22
2014/03/21 16:22
26d
Biotech Stocks Weak on Fear That Gilead Drug Pricing Woes Will Spread By: Adam Feuerstein | 03/21/14 - 11:28 AM EDT Controversy over the $1,000-per-day cost of Gilead Sciences'(GILD) hepatitis C...
2014/03/18 23:22
2014/03/18 23:22
29d
The pivotal study of Exact Sciences'(EXAS) Cologuard stool-based DNA screening test for colon cancer were published in the New England Journal of Medicine tonight, one day earlier than expected due to...
2014/03/18 20:22
2014/03/18 20:22
29d
MannKind's Most Financially Conflicted Sell-Side Analyst Loves Afrezza By: Adam Feuerstein | 03/18/14 - 03:22 PM EDT "... I'll say there is a 90% chance of a positive FDA AdCom outcome." Congrats...
2014/03/18 15:22
2014/03/18 15:22
29d
Prosensa Making the Best of Inconsistent Drisapersen Data By: Adam Feuerstein | 03/18/14 - 11:03 AM EDT Prosensa(RNA) has a lot of clinical data on its Duchenne muscular dystrophy drug drisapersen....
2014/04/09 21:17
2014/04/09 21:17
Latest from Twitter